Background & Aims: Despite effective direct-acting antivirals (DAAs), hepatitis C virus (HCV) prevalence is high among people who inject drugs (PWIDs) and non-adherence to therapy remains a major obstacle towards HCV elimination in this subpopulation. To overcome this issue, we have combined ongoing opioid agonist therapy (OAT) with DAAs in a directly-observed therapy (DOT) setting., Method: From September 2014 until January 2021 PWIDs at high risk of non-adherence to DAA therapy, who were also on OAT, were included into this microelimination project. Individuals received their OAT and DAAs under supervision of healthcare workers as DOT in a pharmacy or low-threshold facility., Results: In total, 504 HCV RNA-positive PWIDs on OAT (387 men, 76.8%; median age: 38 years [IQR 33-45], HIV: 4.6%; hepatitis B: 1.4%) were included into this study. Two thirds reported ongoing intravenous drug use (IDU) and half of them had no permanent housing. Only 41 (8.1%) were lost to follow-up and two (0.4%) died of reasons unrelated to DAA toxicity. Overall, 90.7% of PWIDs achieved sustained virological response 12 weeks after treatment (SVR12) (95% CI: 88.1-93.2%). By excluding those lost to follow-up and hose who had died of causes unrelated to DAAs, the SVR12 rate was 99.1% (95% CI: 98.3-100.0%; modified intention-to-treat analysis). Four PWIDs (0.9%) experienced treatment failure. Over a median follow-up of 24 weeks (IQR 12-39), 27 reinfections (5.9%) were observed in individuals with the highest IDU rates (81.2%). Importantly, even though some were lost to follow-up, all completed their DAA treatment. By using DOT, adherence to DAAs was excellent with only a total of 86 missed doses (0.3% of 25,224 doses)., Conclusions: In this difficult-to-treat population of PWIDs with high rates of IDU , coupling DAA treatment to OAT in a DOT setting resulted in high SVR12 rates equivalent to conventional treatment settings in non-PWID populations., Competing Interests: The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: -Michael Schwarz, Austria (schwarz.medizin@gmail.com): received speaking honoraria from BMS and travel support from BMS, AbbVie, Gilead, and MSD.-Caroline Schwarz, Austria (schwarz.caroline1990@gmail.com): received travel support from Gilead, Abbvie, and Gebro; speaking honoraria from Abbvie and Gilead; and served as a consultant for Gilead.-Angelika Schütz, Austria (angelika.schuetz@suchthilfe.at): no conflicts of interest.-Cornelia Schwanke, Austria (cornelia.schwanke@suchthilfe.at): no conflicts of interest.-Eva Krabb, Austria (eva.krabb@suchthilfe.at) no conflicts of interest.-Raphael Schubert, Austria (raphael.schubert@outlook.at): received travel support from Gilead.-Sophie-Therese Liebich, Austria (sophie-therese.liebich@suchthilfe.at): no conflicts of interest.-David Bauer (david.bauer@meduniwien.ac.at): received travel support from Gilead and Abbvie and speaker fees from Abbvie.-Lukas Burghart (lukas.burghart@gesundheitsverbund.at): no conflicts of interest.-Leonard Brinkmann (leonard-ruben.brinkmann@gesundheitsverbund.at): no conflicts of interest.-Enisa Gutic, Austria (enisa.gutic@extern.gesundheitsverbund.at): received travel support from Gilead and AbbVie.-Thomas Reiberger, Austria (thomas.reiberger@meduniwien.ac.at): received grant support from Abbvie, Boehringer-Ingelheim, Gilead, MSD, Philips Healthcare, Gore; speaking honoraria from Abbvie, Gilead, Gore, Intercept, Roche, MSD; consulting/advisory board fee from Abbvie, Bayer, Boehringer-Ingelheim, Gilead, Intercept, MSD, Siemens; and travel support from Boehringer-Ingelheim, Gilead and Roche.-Hans Haltmayer, Austria (hans.haltmayer@suchthilfe.at): no conflicts of interest.-Michael Gschwantler, Austria (michael.gschwantler@gesundheitsverbund.at): received grant support from Abbvie, Gilead and MSD; speaking honoraria from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Norgine, AstraZeneca, Falk, Shionogi, and MSD; consulting/advisory board fees from Abbvie, Gilead, Intercept, Janssen, BMS, Roche, Alnylam, Norgine, AstraZeneca, Falk, Shionogi and MSD; and travel support from Abbvie and Gilead., (© 2023 The Authors.)